 |
245 Diseases |  |
54 Trials |
|
54 Trials |  |
1419 News |  |
| «12...9101112131415161718192021» |
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Filgrastim Plus Chemotherapy Compared With Filgrastim Alone In Treating Women Undergoing Peripheral Stem Cell Transplantation For Breast Cancer (clinicaltrials.gov) - Feb 19, 2014
P3, N=184, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy in Treating Patients With Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P3, N=116, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | carmustine / Generic mfg.
Trial completion: O(6)-Benzylguanine and Carmustine in Treating Patients With Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1, N=28, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen
Trial completion: Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P3, N=312, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma (clinicaltrials.gov) - Feb 19, 2014
P2, N=40, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | carmustine / Generic mfg.
Trial completion, Surgery: Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme (clinicaltrials.gov) - Feb 19, 2014
P3, N=200, Completed, Sponsor: Radiation Therapy Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jan 30, 2014
P2, N=10, Completed, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed N=40 --> 10
- Trial completion: Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation (clinicaltrials.gov) - Jan 30, 2014
P2, N=10, Completed, Sponsor: Washington University School of Medicine
N=40 --> 10 Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Trial suspension: NCI-2013-00701: O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas (clinicaltrials.gov) - Jan 20, 2014
P1/2, N=24, Suspended, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Suspended
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Mozobil (plerixafor) / Sanofi
Trial initiation date: NCI-2013-00701: O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas (clinicaltrials.gov) - Jan 20, 2014
P1/2, N=24, Suspended, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Suspended Initiation date: Jul 2006 --> Aug 2009
- peripheral blood stem cell transplantation / National Cancer Institute
Trial initiation date, Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - Jan 1, 2014
P=N/A, N=13, Not yet recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Jul 2006 --> Aug 2009 Initiation date: Oct 2013 --> Oct 2014
- Trial termination: Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (clinicaltrials.gov) - Nov 20, 2013
P2, N=1, Terminated, Sponsor: Texas Oncology Cancer Center
Initiation date: Oct 2013 --> Oct 2014 Recruiting --> Terminated; Insufficient accruals
- Enrollment change: Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (clinicaltrials.gov) - Nov 20, 2013
P2, N=1, Terminated, Sponsor: Texas Oncology Cancer Center
Recruiting --> Terminated; Insufficient accruals N=20 --> 1
- cyclophosphamide / Generic mfg.
Trial completion: Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia (clinicaltrials.gov) - Oct 31, 2013
P2, N=150, Completed, Sponsor: German CLL Study Group
N=20 --> 1 Active, not recruiting --> Completed
- | carmustine / Generic mfg.
Trial completion, Surgery: Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Oct 28, 2013
P1/2, N=24, Completed, Sponsor: Nobelpharma
Active, not recruiting --> Completed Active, not recruiting --> Completed
- New P2 trial: Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma (clinicaltrials.gov) - Oct 23, 2013
P2, N=50, Not yet recruiting, Sponsor: Washington University School of Medicine
- 90Y-BC8-DOTA / Fred Hutchinson Cancer Center
Enrollment change: Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies (clinicaltrials.gov) - Oct 17, 2013
P1/2, N=44, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=70 --> 44
- 90Y-BC8-DOTA / Fred Hutchinson Cancer Center
Enrollment open: Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies (clinicaltrials.gov) - Oct 17, 2013
P1/2, N=44, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
N=70 --> 44 Not yet recruiting --> Recruiting
- carmustine / Generic mfg.
Trial completion: Radiation Therapy Followed by Carmustine in Treating Patients Who Have Supratentorial Glioblastoma Multiforme (clinicaltrials.gov) - Oct 7, 2013
P2, N=80, Completed, Sponsor: Radiation Therapy Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Sep 15, 2013
P3, N=460, Completed, Sponsor: EBMT Solid Tumors Working Party
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| aprepitant oral / Generic mfg.
Trial completion: A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208) (clinicaltrials.gov) - Sep 3, 2013
P3, N=307, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- gemcitabine / Generic mfg.
Enrollment change: Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease (clinicaltrials.gov) - Aug 26, 2013
P2, N=146, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed N=72 --> 146
- gemcitabine / Generic mfg.
Trial completion: Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease (clinicaltrials.gov) - Aug 26, 2013
P2, N=146, Completed, Sponsor: Stanford University
N=72 --> 146 Active, not recruiting --> Completed
- 90Y-BC8-DOTA / Fred Hutchinson Cancer Center
New P1/2 trial: Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies (clinicaltrials.gov) - Aug 11, 2013
P1/2, N=44, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: HOVON-44: Chemotherapy and Peripheral Stem Cell Transplant With or Without Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Aug 7, 2013
P3, N=340, Completed, Sponsor: Commissie Voor Klinisch Toegepast Onderzoek
Active, not recruiting --> Completed Recruiting --> Completed
- Istodax (romidepsin) / Astellas, BMS
New P2 trial: A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 24, 2013
P2, N=33, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Trial completion: GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 22, 2013
P2, N=14, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- Enrollment change: PRECIS: Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients (clinicaltrials.gov) - Jul 7, 2013
P2, N=140, Recruiting, Sponsor: Centre Rene Huguenin
Active, not recruiting --> Completed N=100 --> 140
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia (clinicaltrials.gov) - Jul 2, 2013
P2, N=30, Completed, Sponsor: University of Nebraska
N=100 --> 140 Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed: Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma (clinicaltrials.gov) - May 28, 2013
P2, N=101, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 21, 2013
P3, N=397, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Recruiting --> Completed
- | melphalan / Generic mfg.
Enrollment change: SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma (clinicaltrials.gov) - May 20, 2013
P3, N=899, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Completed N=500 --> 899
- | melphalan / Generic mfg.
Trial completion: SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma (clinicaltrials.gov) - May 20, 2013
P3, N=899, Completed, Sponsor: Southwest Oncology Group
N=500 --> 899 Active, not recruiting --> Completed
- Trial initiation date: High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - May 6, 2013
P2, N=451, Completed, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Initiation date: Jul 1991 --> Dec 1991
- Trial completion: High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors (clinicaltrials.gov) - May 6, 2013
P2, N=451, Completed, Sponsor: Roswell Park Cancer Institute
Initiation date: Jul 1991 --> Dec 1991 Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma (clinicaltrials.gov) - Apr 25, 2013
P2, N=98, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- vadacabtagene leraleucel (JCAR015) / BMS
New P1 trial: High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 23, 2013
P1, N=18, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- Gliadel Wafer (carmustine implant) / Eisai, Azurity Pharma, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 16, 2013
P2, N=68, Active, not recruiting, Sponsor: University of Nebraska
Active, not recruiting --> Completed Completed --> Active, not recruiting
- | Trial completion: Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma (clinicaltrials.gov) - Apr 16, 2013
P3, N=170, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Completed --> Active, not recruiting Active, not recruiting --> Completed
- || Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
New P3 trial: FIL FLAZ12: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) (clinicaltrials.gov) - Apr 7, 2013
P3, N=265, Recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
- ||| Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed: Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant (clinicaltrials.gov) - Mar 28, 2013
P2, N=52, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- carmustine / Generic mfg.
Trial withdrawal: Carmustine and O(6)-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme (clinicaltrials.gov) - Mar 25, 2013
P2, N=0, Withdrawn, Sponsor: Duke University
Recruiting --> Active, not recruiting Active, not recruiting --> Withdrawn
- Leukine (sargramostim) / Partner Therap, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change: GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma (clinicaltrials.gov) - Mar 3, 2013
P2, N=14, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Withdrawn N=29 --> 14
- carmustine / Generic mfg.
Trial completion: Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the Brain (clinicaltrials.gov) - Feb 14, 2013
P1, N=56, Completed, Sponsor: Duke University
N=29 --> 14 Active, not recruiting --> Completed
- irinotecan / Generic mfg., carmustine / Generic mfg.
Trial completion: Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma (clinicaltrials.gov) - Feb 14, 2013
P1, N=36, Completed, Sponsor: Duke University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- topotecan / Generic mfg.
Trial completion: Chemotherapy in Treating Patients With Recurrent Malignant Glioma (clinicaltrials.gov) - Feb 14, 2013
P1, N=36, Completed, Sponsor: Duke University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- carmustine / Generic mfg.
Trial completion, Metastases: O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma (clinicaltrials.gov) - Feb 5, 2013
P2, N=12, Completed, Sponsor: University of Chicago
Active, not recruiting --> Completed Active, not recruiting --> Completed
- carmustine / Generic mfg.
Trial completion: O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors (clinicaltrials.gov) - Feb 3, 2013
P1, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | carmustine / Generic mfg.
Trial completion: S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - Jan 27, 2013
P3, N=183, Completed, Sponsor: Southwest Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: CBV: Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease (clinicaltrials.gov) - Jan 22, 2013
P2, N=147, Completed, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed